The evolution of smartwatches that can check your blood pressure and track your sleep rhythms can be traced to clinical trials in St. Paul that have overcome historical barriers by recruiting minority participants.
Fairview Frontiers has recruited almost 1,000 participants this year alone in studies seeking to elevate smartwatches from fitness novelties to diagnostic health care machines. Almost 34% of the participants are minority members, doubling last year's rate and fueling the growth that made Frontiers a go-to recruiter when Apple, Garmin and other companies launch studies.
The diversity is a breakthrough itself but also an important step in research to determine if optical sensors in smartwatches can identify sleep apnea, irregular heartbeats and other health problems, said Andrew Snyder, director of clinical trials for M Health Fairview, the health system that oversees Frontiers.
"How do they translate that to an actual clinical diagnosis? That's what they're working on," he said. "All of these sensors are optically based, which means they are trying to read things through light. That's one of the reasons why we need so many people with different colored skin, because the results might be quite different."
Frontiers leaders credited their success to targeted recruiting and a move last year to an accessible location in the former St. Joseph's Hospital.
Minority mistrust in research is historically associated with infamous studies, such as the federally funded Tuskegee experiment in the mid-20th century when doctors feigned treatment of syphilis in Black men in Alabama to understand the course of the sexually transmitted disease. But numerous other factors play a role, including higher poverty rates among minority members that make it logistically harder for them to volunteer.
As a result, research has been inadequate when it comes to how certain drugs and treatments affect minority populations. Mysteries such as the prevalence of gout among Hmong people also remained unsolved until researchers finally amassed enough study participants to identify genetic factors.
A 2021 study by Mayo Clinic researchers showed some progress: minority participation in federally funded trials increased from 3% in 2008 to 11% in 2018, but participation in commercially funded research lagged behind.